Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is ARIPIPRAZOLE USP, with a corresponding US DMF Number 19554.
Remarkably, this DMF maintains an Active status since its submission on June 28, 2006, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of January 15, 2014, and payment made on February 22, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II